286456-42-6
中文名称
3-(2,5-二氟苯基)-7-(1,1-二甲基乙基)-6-[(1-甲基-1H-1,2,4-,三唑-5-基)甲氧基]-1,2,4-4-三唑[4,3-B]哒嗪
英文名称
L-838417
CAS
286456-42-6
分子式
C19H19F2N7O
分子量
399.4
MOL 文件
286456-42-6.mol
286456-42-6 结构式
基本信息
中文别名
化合物 T197023-(2,5-二氟苯基)-7-(1,1-二甲基乙基)-6-[(1-甲基-1H-1,2,4-,三唑-5-基)甲氧基]-1,2,4-4-三唑[4,3-B]哒嗪
英文别名
L-838417 L-838417_x000b_
5-({[7-tert-butyl-3-(2,5-difluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl]oxy}methyl)-1-methyl-1,2,4-triazole
7-(tert-Butyl)-3-(2,5-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4,-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-b]pyridazine
1,2,4-Triazolo[4,3-b]pyridazine,3-(2,5-difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4-triazol-5-yl)methoxy]-
3-(2,5-Difluorophenyl)-7-(1,1-dimethylethyl)-6-[(1-methyl-1H-1,2,4,-triazol-5-yl)methoxy]-1,2,4-triazolo[4,3-β]pyridazine
所属类别
生物化工：激动剂抑制剂常见问题列表
生物活性
L-838417 是GABAA 受体 α2, α3 和 α5 亚型的选择性部分激动剂，是 α1 亚型的拮抗剂，其对 α1β3γ2、α2β3γ2、α3β3γ2、α4β3γ2、α5β3γ2 和 α6β3γ2 的Ki 值分别为 0.79 nM、0.67 nM、1.67 nM、267 nM、2.25 nM 和 2183 nM。靶点
Ki: 0.79 nM (α1β3γ2), 0.67 nM (α2β3γ2), 1.67 nM (α3β3γ2), 267 nM (α4β3γ2), 2.25 nM (α5β3γ2) and 2183 nM (α6β3γ2).
体内研究
L-838417 (1.0 mg/kg) produces anxiolytic effects in adult rat, as indexed by a transformation of social avoidance into preference and an increase in social investigation.
L-838417 (2.0 mg/kg) eliminates social avoidance, but has no anxiolytic effects on social investigation.
L-838417 (0.5 mg/kg) reverses the anxiogenic effects of prior stress regardless of age, but with doses ≥ 1 mg/kg decreases social investigation, an effect possibly due in part to locomotor-impairing effects of this compound.
| Animal Model: | Male and female adolescent and adult Sprague–Dawley rats. |
| Dosage: | 0, 0.5, 1.0, 2.0, or 4.0 mg/kg. |
| Administration: | IP. |
| Result: |
Adolescents required a higher dose (2 mg/kg) to attenuate their social avoidance.
The lowest dose of 0.5 mg/kg was sufficient to reverse the anxiogenic effects of repeated restraint as reflected by a significant increase in the coefficient relative to vehicle-treated animals. |